A new approach for enhancing differential selectivity of drugs to cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Selective targeting of cancer cells is crucial for effective anticancer therapies.
• Heat shock protein 90 (Hsp90) inhibitors are a promising class of anticancer agents.
• Intracellular pH gradients differ between normal and cancer cells, offering a potential target for drug selectivity.

Purpose of the Study:

• To investigate a novel mechanism for optimizing Hsp90 inhibitor selectivity towards cancer cells.
• To explore the role of physicochemical properties, specifically basicity, in Hsp90 inhibitor efficacy.
• To leverage differential intracellular pH gradients for enhanced anticancer drug targeting.

Main Methods:

• Evaluated five Hsp90 inhibitors with varying basic and neutral properties.
• Utilized antiproliferation assays on cells with different lysosomal pH levels.
• Quantitatively determined intracellular inhibitor concentrations in relevant cellular compartments.

Main Results:

• Basic Hsp90 inhibitors showed reduced activity in normal cells (low lysosomal pH) but enhanced activity in cancer cells (elevated lysosomal pH).
• Neutral Hsp90 inhibitors did not exhibit similar selectivity enhancements.
• Intracellular concentration measurements confirmed the mechanistic basis for observed selectivity.

Conclusions:

• Hsp90 inhibitors with optimized basicity and physicochemical properties demonstrate superior selectivity for cancer cells over neutral counterparts.
• This strategy of exploiting intracellular pH gradients holds potential for improving selectivity of other anticancer agents.
• Findings suggest a promising approach for developing more targeted and effective cancer therapies.